The bleeding disorders market was valued at $13.78 Billion in 2022 and is estimated to reach $25.97 Billion by 2032, exhibiting a CAGR of 6.6% from 2023 to 2032.
Bleeding disorders are a group of conditions characterized by abnormal bleeding due to the deficiency or dysfunction of certain clotting factors in the blood. Normally, when a person experiences an injury or cut, the body forms a clot to stop bleeding. However, in a person with a bleeding disorder, this process is impaired or absent, which may lead to abnormal or excessive bleeding. Hemophilia is the most well-known and common bleeding disorder, which affects mostly males and may result in serious and life-threatening bleeding episodes. Von Willebrand disease is another common bleeding disorder that affects both males and females and may lead to prolonged bleeding after injury or surgery.
Major factors that drive the growth of the bleeding disorders market Include rapid advancements in treatment of bleeding disorders; Increase in number of patients suffering from hemophilia A, hemophilia B, and other bleeding disorders. For instance, according to the Centers for Disease Control and Prevention (CDC) 2022, 33,000 males in the U.S. live with the bleeding disorder.
Furthermore, favorable government initiatives for hemophilia management, Increase in number of awareness programs regarding bleeding disorder treatment and rise in number of clinical trials for the development of antihemophilic drugs boost the growth of bleeding disorders market. In addition, the Increase in target population, Increase in diagnosis rate, and surge in the use of prophylactic treatment for hemophilia propel the market growth.
However, the high cost of hemophilia treatment, and serious adverse effects associated with plasma derived products are expected to restrict the growth of bleeding disorders market. On the contrary, surge in healthcare expenditure, and unmet medical demands to get better treatment options for hemophilia in developing countries are expected to create immense opportunities for the expansion of the global market in the future.
The bleeding disorders market is segmented on the basis of disease type, treatment type, distribution channel and region. On the basis of disease type, the market is classified into hemophilia A, hemophilia B, Von Willebrand disease and others. On the basis of treatment type, the market is classified into factor replacement therapy, and drug therapy (desmopressin, antifibrinolytics, fibrin sealant). The factor replacement therapy segment is further bifurcated into plasma-derived coagulation factor concentrates, and recombinant coagulation factor concentrates. On the basis of distribution channel, the bleeding disorders market is segmented into hospital pharmacies, drugs stores and retail pharmacies, and online pharmacies. On the basis of region, the market is analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and Rest of Europe), Asia-Pacific (China, Japan, Australia, India, South Korea, and Rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and Rest of LAMEA).
Major players profiled in the report are Bayer AG, CSL Ltd. (CSL Behring), F. Hoffmann-La Roche AG, Grifols, S.A., Medexus Pharma, Inc., Novo Nordisk A/S, Octapharma AG, Pfizer Inc., SANOFI CORPORATION, and Takeda Pharmaceutical Company Limited. The major players in the market have adopted investment, partnership and product approvals as key developmental strategies to improve the product portfolio of the bleeding disorders market.
Bleeding disorders are a group of conditions characterized by abnormal bleeding due to the deficiency or dysfunction of certain clotting factors in the blood. Normally, when a person experiences an injury or cut, the body forms a clot to stop bleeding. However, in a person with a bleeding disorder, this process is impaired or absent, which may lead to abnormal or excessive bleeding. Hemophilia is the most well-known and common bleeding disorder, which affects mostly males and may result in serious and life-threatening bleeding episodes. Von Willebrand disease is another common bleeding disorder that affects both males and females and may lead to prolonged bleeding after injury or surgery.
Major factors that drive the growth of the bleeding disorders market Include rapid advancements in treatment of bleeding disorders; Increase in number of patients suffering from hemophilia A, hemophilia B, and other bleeding disorders. For instance, according to the Centers for Disease Control and Prevention (CDC) 2022, 33,000 males in the U.S. live with the bleeding disorder.
Furthermore, favorable government initiatives for hemophilia management, Increase in number of awareness programs regarding bleeding disorder treatment and rise in number of clinical trials for the development of antihemophilic drugs boost the growth of bleeding disorders market. In addition, the Increase in target population, Increase in diagnosis rate, and surge in the use of prophylactic treatment for hemophilia propel the market growth.
However, the high cost of hemophilia treatment, and serious adverse effects associated with plasma derived products are expected to restrict the growth of bleeding disorders market. On the contrary, surge in healthcare expenditure, and unmet medical demands to get better treatment options for hemophilia in developing countries are expected to create immense opportunities for the expansion of the global market in the future.
The bleeding disorders market is segmented on the basis of disease type, treatment type, distribution channel and region. On the basis of disease type, the market is classified into hemophilia A, hemophilia B, Von Willebrand disease and others. On the basis of treatment type, the market is classified into factor replacement therapy, and drug therapy (desmopressin, antifibrinolytics, fibrin sealant). The factor replacement therapy segment is further bifurcated into plasma-derived coagulation factor concentrates, and recombinant coagulation factor concentrates. On the basis of distribution channel, the bleeding disorders market is segmented into hospital pharmacies, drugs stores and retail pharmacies, and online pharmacies. On the basis of region, the market is analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and Rest of Europe), Asia-Pacific (China, Japan, Australia, India, South Korea, and Rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and Rest of LAMEA).
Major players profiled in the report are Bayer AG, CSL Ltd. (CSL Behring), F. Hoffmann-La Roche AG, Grifols, S.A., Medexus Pharma, Inc., Novo Nordisk A/S, Octapharma AG, Pfizer Inc., SANOFI CORPORATION, and Takeda Pharmaceutical Company Limited. The major players in the market have adopted investment, partnership and product approvals as key developmental strategies to improve the product portfolio of the bleeding disorders market.
Key Benefits For Stakeholders
- This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the bleeding disorders market analysis from 2022 to 2032 to identify the prevailing bleeding disorders market opportunities.
- The market research is offered along with information related to key drivers, restraints, and opportunities.
- Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
- In-depth analysis of the bleeding disorders market segmentation assists to determine the prevailing market opportunities.
- Major countries in each region are mapped according to their revenue contribution to the global market.
- Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
- The report Includes the analysis of the regional as well as global bleeding disorders market trends, key players, market segments, application areas, and market growth strategies.
Key Market Segments
By Disease Type
- Hemophilia A
- Hemophilia B
- Von Willebrand Disease
- Others
By Treatment Type
- Factor Replacement Therapy
- Type
- Recombinant coagulation factor concentrates
- Plasma derived coagulation factor concentrates
- Drug Therapy
By Distribution Channel
- Hospital Pharmacies
- Drug stores and retail pharmacies
- Online pharmacies
By Region
- North America
- U.S.
- Canada
- Mexico
- Europe
- Germany
- France
- UK
- Italy
- Spain
- Rest of Europe
- Asia-Pacific
- Japan
- China
- Australia
- India
- South Korea
- Rest of Asia-Pacific
- LAMEA
- Brazil
- Saudi Arabia
- South Africa
- Rest of LAMEA
Key Market Players
- Medexus Pharma, Inc.
- Bayer AG
- Novo Nordisk A/S
- Grifols, S.A.
- Octapharma AG
- Takeda Pharmaceutical Company Limited
- CSL Limited
- Pfizer Inc.
- Sanofi
- F. Hoffmann-La Roche Ltd.
Table of Contents
CHAPTER 1: INTRODUCTION
CHAPTER 2: EXECUTIVE SUMMARY
CHAPTER 3: MARKET OVERVIEW
CHAPTER 4: BLEEDING DISORDERS MARKET, BY DISEASE TYPE
CHAPTER 5: BLEEDING DISORDERS MARKET, BY TREATMENT TYPE
CHAPTER 6: BLEEDING DISORDERS MARKET, BY DISTRIBUTION CHANNEL
CHAPTER 7: BLEEDING DISORDERS MARKET, BY REGION
CHAPTER 8: COMPETITIVE LANDSCAPE
CHAPTER 9: COMPANY PROFILES
List of Tables
List of Figures
Executive Summary
According to a new report, titled, 'Bleeding Disorders Market,' The bleeding disorders market was valued at $13.8 billion in 2022, and is estimated to reach $26 billion by 2032, growing at a CAGR of 6.6% from 2023 to 2032. A bleeding disorder is a medical condition characterized by inability of a person to form blood clots properly. Blood clots are essential in stopping bleeding after an injury or trauma. Bleeding disorders may lead to excessive bleeding, even with minor injuries, and may also cause internal bleeding in some cases.Key factors driving the growth of the bleeding disorders market include the surge in prevalence of bleeding disorders such as hemophilia A, hemophilia B, and Von Willebrand disease, which further required factor replacement therapy and drug therapy. For instance, according to the Hemophilia News Today of BioNews, Inc. report, published in April 2021, an estimated 400,000 people globally have severe hemophilia. In addition, the development of newer and more effective treatment options, such as extended half-life factor products, gene therapy, and non-factor replacement therapies, is driving growth in the bleeding disorders market.
Moreover, the rise in the number of clinical trials for developing safe and effective medicines against bleeding disorders across the world drives the growth of the bleeding disorders market during forecast period. For instance, In December 2022, Pfizer Inc. announced positive top-line results from the Phase 3 BENEGENE-2 study (NCT03861273) evaluating fidanacogene elaparvovec, an investigational gene therapy, for the treatment of adult males with moderately severe to severe hemophilia B.
The market offers growth opportunities to the key players in the market including the rise in awareness regarding bleeding disorders in developing countries, rise in number of research regarding treatment of bleeding disorders. And the rise in demand for medicines of bleeding disorders across the globe also provides growth opportunities for the market. As a result, the key players engaged in the bleeding disorders industry have invested in R&D and increasing their production are expected to gain high traction and provide lucrative opportunity for the growth of bleeding disorders market.
The bleeding disorders market is segmented on the basis of disease type, treatment type, distribution channel and region. On the basis of disease type, the market is classified into hemophilia A, hemophilia B, Von Willebrand disease and others. On the basis of treatment type, the market is classified into factor replacement therapy, and drug therapy (desmopressin, antifibrinolytics, fibrin sealant). The factor replacement therapy segment is further bifurcated into plasma-derived coagulation factor concentrates, and recombinant coagulation factor concentrates. On the basis of distribution channel, the bleeding disorders market is segmented into hospital pharmacies, drugs stores and retail pharmacies, and online pharmacies. Region wise, the market is analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and rest of Europe), Asia-Pacific (China, Japan, Australia, India, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and rest of LAMEA).
The key players profiled in the study include Bayer AG, CSL Ltd. (CSL Behring), F. Hoffmann-La Roche AG, Grifols, S.A., Medexus Pharma, Inc., Novo Nordisk A/S, Octapharma AG, Pfizer Inc., SANOFI CORPORATION, and Takeda Pharmaceutical Company Limited. The players in the market such as CSL Ltd. (CSL Behring), Pfizer Inc., Novo Nordisk A/S, SANOFI CORPORATION, and Takeda Pharmaceutical Company have been actively engaged in the adoption of various strategies such as investment, partnership and product approvals to remain competitive and gain an advantage over the competitors in the market. For instance, in January 2022, Takeda Pharmaceutical Company Limited announced that the U.S. Food and Drug Administration (FDA) approved VONVENDI [Von Willebrand factor (Recombinant)] for routine prophylaxis to reduce the frequency of bleeding episodes in patients with severe Type 3 Von Willebrand disease (VWD) receiving on-demand therapy. VONVENDI is the only recombinant Von Willebrand factor (VWF) replacement therapy, and the first and only treatment to reduce the frequency of bleeding episodes for severe Type 3 VWD approved by the FDA for routine prophylactic use.
Key Market Insights
- By disease type, the hemophilia A segment was the highest revenue contributor to the market in 2022 and is estimated to reach $13,198.96 million by 2032. The same segment is expected to be the fastest-growing segment with a CAGR of 6.6% during the forecast period.
- By treatment type, the factor replacement therapy segment was the highest revenue contributor to the market in 2022. The same segment is expected to witness the highest CAGR of 6.7%.
- Based on the distribution channel, the drugs stores and retail pharmacies segment was the highest revenue contributor to the market in 2022. However, the hospital pharmacies segment is estimated to be the fastest-growing segment with a CAGR of 7.0% during the forecast period.
- Based on region, North America accounted for a major share of the bleeding disorders market in 2022 and is expected to maintain its dominance during the forecast period. Asia-Pacific is expected to witness the highest CAGR of 8.0% during the forecast period.
Companies Mentioned
- Medexus Pharma, Inc.
- Bayer AG
- Novo Nordisk A/S
- Grifols, S.A.
- Octapharma AG
- Takeda Pharmaceutical Company Limited
- CSL Limited
- Pfizer Inc.
- Sanofi
- F. Hoffmann-La Roche Ltd.
Methodology
The analyst offers exhaustive research and analysis based on a wide variety of factual inputs, which largely include interviews with industry participants, reliable statistics, and regional intelligence. The in-house industry experts play an instrumental role in designing analytic tools and models, tailored to the requirements of a particular industry segment. The primary research efforts include reaching out participants through mail, tele-conversations, referrals, professional networks, and face-to-face interactions.
They are also in professional corporate relations with various companies that allow them greater flexibility for reaching out to industry participants and commentators for interviews and discussions.
They also refer to a broad array of industry sources for their secondary research, which typically include; however, not limited to:
- Company SEC filings, annual reports, company websites, broker & financial reports, and investor presentations for competitive scenario and shape of the industry
- Scientific and technical writings for product information and related preemptions
- Regional government and statistical databases for macro analysis
- Authentic news articles and other related releases for market evaluation
- Internal and external proprietary databases, key market indicators, and relevant press releases for market estimates and forecast
Furthermore, the accuracy of the data will be analyzed and validated by conducting additional primaries with various industry experts and KOLs. They also provide robust post-sales support to clients.
LOADING...
